Borghi Alessandro, Flacco Maria Elena, Pacetti Lucrezia, Schettini Natale, Toni Giulia, Corazza Monica
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.
J Low Genit Tract Dis. 2025 Jan 1;29(1):88-92. doi: 10.1097/LGT.0000000000000854. Epub 2024 Dec 2.
The phenomenon of topical corticosteroid (TC) phobia (TCP) poses a challenge to the adherence of patients requiring prolonged treatments, particularly those with conditions like atopic dermatitis. Nonadherence to treatment significantly contributes to the inadequate control of diseases. This study aimed to evaluate TCP among women suffering from vulvar lichen sclerosus (VLS) and its potential impact on treatment adherence and therapeutic outcomes.
This observational, prospective study involved adult patients who received their first histological diagnosis of VLS and underwent a 12-week corticosteroid treatment regimen at the authors' Vulva Unit between June 2022 and September 2023. All participants completed the validated TOPICOP questionnaire, which assesses concerns, worries, and beliefs regarding TC usage. Baseline and 12-week control visit assessments were conducted to evaluate subjective and objective parameters of VLS. Patient adherence to treatment was monitored through diary entries.
Among the 50 patients included (with a mean age of 64.9 ± 13.5 years), more than half (58%) had prior experience with TC treatments and 10.3% had used corticosteroids for vulvar symptoms without a precise diagnosis. The median global TOPICOP score was 19.4% (interquartile range = 5.6-36.1), with a corresponding median value of 7.0 (interquartile range = 2.0-13.0). A total of 41 patients (82.2%) adhered to the study treatment, which proved highly effective in alleviating symptoms and improving signs of VLS. Multivariate analysis revealed that neither treatment adherence nor effectiveness were significantly associated with the level of TCP.
Among the authors' VLS patients, TCP was relatively low and did not negatively impact treatment adherence to corticosteroids. Moreover, TCP did not influence the effectiveness of TC therapy, as it did not affect adherence.
局部糖皮质激素恐惧症(TCP)现象给需要长期治疗的患者,尤其是患有特应性皮炎等疾病的患者的依从性带来了挑战。不坚持治疗会显著导致疾病控制不佳。本研究旨在评估患有外阴硬化性苔藓(VLS)的女性中的TCP及其对治疗依从性和治疗结果的潜在影响。
这项观察性前瞻性研究纳入了在2022年6月至2023年9月期间在作者的外阴科接受首次VLS组织学诊断并接受为期12周糖皮质激素治疗方案的成年患者。所有参与者均完成了经过验证的TOPICOP问卷,该问卷评估了对使用局部糖皮质激素的担忧、顾虑和信念。进行基线和12周对照访视评估以评估VLS的主观和客观参数。通过日记记录监测患者的治疗依从性。
在纳入的50名患者中(平均年龄64.9±13.5岁),超过一半(58%)曾有过局部糖皮质激素治疗经历,10.3%曾在未明确诊断的情况下使用糖皮质激素治疗外阴症状。TOPICOP全球评分中位数为19.4%(四分位间距=5.6-36.1),相应的中位数为7.0(四分位间距=2.0-13.0)。共有41名患者(82.2%)坚持研究治疗,该治疗在缓解症状和改善VLS体征方面证明非常有效。多变量分析显示,治疗依从性和有效性均与TCP水平无显著关联。
在作者的VLS患者中,TCP相对较低,并且对糖皮质激素治疗的依从性没有负面影响。此外,TCP不影响局部糖皮质激素治疗的有效性,因为它不影响依从性。